AR050851A1 - CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENGLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR THEIR PREPARATION AND METHODS OF USE OF THE SAME - Google Patents
CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENGLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR THEIR PREPARATION AND METHODS OF USE OF THE SAMEInfo
- Publication number
- AR050851A1 AR050851A1 ARP050103612A ARP050103612A AR050851A1 AR 050851 A1 AR050851 A1 AR 050851A1 AR P050103612 A ARP050103612 A AR P050103612A AR P050103612 A ARP050103612 A AR P050103612A AR 050851 A1 AR050851 A1 AR 050851A1
- Authority
- AR
- Argentina
- Prior art keywords
- growth hormone
- human growth
- glicerol
- ramified
- polyethylenglycol
- Prior art date
Links
- 102000002265 Human Growth Hormone Human genes 0.000 title abstract 6
- 108010000521 Human Growth Hormone Proteins 0.000 title abstract 6
- 239000000854 Human Growth Hormone Substances 0.000 title abstract 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 230000006320 pegylation Effects 0.000 abstract 2
- 206010012559 Developmental delay Diseases 0.000 abstract 1
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se refiere a la PEGilacion de la hormona del crecimiento humana (hGH) usando un PEG ramificado con glicerol. También se refiere a procesos para la PEGilacion de hGH. Además, se refiere a composiciones farmacéuticas que comprenden la hGH PEGilada. Otra realizacion es el uso de la hGH PEGilada para el tratamiento de trastornos del crecimiento y del desarrollo.It refers to the PEGylation of human growth hormone (hGH) using a PEG branched with glycerol. It also refers to processes for the PEGylation of hGH. In addition, it refers to pharmaceutical compositions comprising PEGylated hGH. Another embodiment is the use of PEGylated hGH for the treatment of growth and development disorders.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60594504P | 2004-08-31 | 2004-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR050851A1 true AR050851A1 (en) | 2006-11-29 |
Family
ID=35708806
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103612A AR050851A1 (en) | 2004-08-31 | 2005-08-29 | CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENGLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR THEIR PREPARATION AND METHODS OF USE OF THE SAME |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP1789092A2 (en) |
JP (1) | JP2008511610A (en) |
KR (1) | KR20070042567A (en) |
CN (1) | CN101010105A (en) |
AP (1) | AP2007003919A0 (en) |
AR (1) | AR050851A1 (en) |
AU (1) | AU2005278903A1 (en) |
BR (1) | BRPI0515118A (en) |
CA (1) | CA2577999A1 (en) |
CR (1) | CR8942A (en) |
EA (1) | EA200700380A1 (en) |
EC (1) | ECSP077281A (en) |
GT (1) | GT200500235A (en) |
IL (1) | IL181085A0 (en) |
MA (1) | MA28908B1 (en) |
MX (1) | MX2007002441A (en) |
NL (1) | NL1029828C2 (en) |
NO (1) | NO20071322L (en) |
PE (1) | PE20060654A1 (en) |
TN (1) | TNSN07078A1 (en) |
TW (1) | TW200621291A (en) |
UY (1) | UY29088A1 (en) |
WO (1) | WO2006024953A2 (en) |
ZA (1) | ZA200701802B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
BR9812267B1 (en) | 1997-07-14 | 2013-11-26 | Recombinant Growth Hormone. | |
EP1144613B2 (en) | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
EP1834963A1 (en) * | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
MX2008014358A (en) * | 2006-05-12 | 2008-11-24 | Dong A Pharm Co Ltd | Polyethylene glycol-interferon alpha conjugate. |
JP2008069073A (en) * | 2006-09-12 | 2008-03-27 | Yokohama Tlo Co Ltd | Lactoferrin conjugate and its manufacturing method |
KR101079993B1 (en) | 2006-11-17 | 2011-11-04 | 동아제약주식회사 | Polyethylene glycol-G-CSF conjugate |
CL2008002399A1 (en) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Substantially pure conjugate having a polymeric portion, a protein portion (interferon alpha 2b) and an aliphatic binder of 1 to 10 carbon atoms, useful in the treatment of hepatitis b or c. |
WO2010011096A2 (en) * | 2008-07-23 | 2010-01-28 | Hanmi Pharmaceutical Co., Ltd. | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
AU2009276458B2 (en) | 2008-07-31 | 2014-06-19 | Pharmaessentia Corp. | Peptide-polymer conjugates |
US8535655B2 (en) | 2008-10-10 | 2013-09-17 | Polyactiva Pty Ltd. | Biodegradable polymer—bioactive moiety conjugates |
PT2355853T (en) * | 2008-10-10 | 2017-03-15 | Polyactiva Pty Ltd | Biodegradable polymer - bioactive moiety conjugates |
SI2340271T1 (en) | 2008-10-10 | 2019-08-30 | Polyactiva Pty Ltd. | Polymer-bioactive agent conjugates |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
US9849188B2 (en) | 2009-06-08 | 2017-12-26 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
JP6086528B2 (en) | 2009-08-06 | 2017-03-01 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Growth hormone with long-term in vivo efficacy |
CN101831067A (en) * | 2010-05-31 | 2010-09-15 | 王二新 | Polyethylene glycol ester conjugate and application thereof in medicine preparation |
EP2446898A1 (en) | 2010-09-30 | 2012-05-02 | Laboratorios Del. Dr. Esteve, S.A. | Use of growth hormone to enhance the immune response in immunosuppressed patients |
CN102367290B (en) * | 2011-04-26 | 2013-05-08 | 厦门赛诺邦格生物科技有限公司 | Chain-functionalized multi-level branched polyethylene glycol and synthesis method thereof |
WO2014110867A1 (en) * | 2013-01-17 | 2014-07-24 | 厦门赛诺邦格生物科技有限公司 | Monofunctional branched polyethyleneglycol and bio-related substance modified by same |
CN104877127B (en) | 2015-06-23 | 2017-11-10 | 厦门赛诺邦格生物科技股份有限公司 | A kind of eight arms polyethyleneglycol derivative, preparation method and its bio-related substance of modification |
SI3215193T1 (en) | 2014-11-06 | 2024-02-29 | Pharmaessentia Corporation | Dosage regimen for pegylated interferon |
JP7227633B2 (en) * | 2017-12-29 | 2023-02-22 | エフ. ホフマン-ラ ロシュ エージー. | Methods for providing PEGylated protein compositions |
EP3731872B1 (en) | 2017-12-29 | 2021-11-24 | F. Hoffmann-La Roche AG | Process for providing pegylated protein composition |
JP7137625B2 (en) * | 2017-12-29 | 2022-09-14 | エフ.ホフマン-ラ ロシュ アーゲー | Methods for providing PEGylated protein compositions |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
JP3092531B2 (en) * | 1996-11-05 | 2000-09-25 | 日本油脂株式会社 | Method for producing imidyl succinate-substituted polyoxyalkylene derivative |
BR9812267B1 (en) * | 1997-07-14 | 2013-11-26 | Recombinant Growth Hormone. | |
JP3921781B2 (en) * | 1998-02-12 | 2007-05-30 | 日本油脂株式会社 | Carboxyl group-containing polyoxyalkylene compound |
EP1144613B2 (en) * | 1999-01-14 | 2020-05-06 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
IL162031A0 (en) * | 2001-11-20 | 2005-11-20 | Pharmacia Corp | Chemically-modified human growth hormone conjugates |
AP2005003246A0 (en) * | 2002-09-09 | 2005-03-31 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
JP4412461B2 (en) * | 2002-11-20 | 2010-02-10 | 日油株式会社 | Modified bio-related substance, production method thereof and intermediate |
WO2004060406A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Polymeric reagents comprising a ketone or a related functional group |
TR201907313T4 (en) * | 2003-05-23 | 2019-06-21 | Nektar Therapeutics | PEG derivatives containing two PEG chains. |
-
2005
- 2005-08-25 EA EA200700380A patent/EA200700380A1/en unknown
- 2005-08-25 CA CA002577999A patent/CA2577999A1/en not_active Abandoned
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/en active Pending
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/en unknown
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/en not_active IP Right Cessation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/en unknown
- 2005-08-25 EP EP05784225A patent/EP1789092A2/en not_active Withdrawn
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/en active Application Filing
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/en not_active Application Discontinuation
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/en active Pending
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/en not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/en unknown
- 2005-08-29 UY UY29088A patent/UY29088A1/en not_active Application Discontinuation
- 2005-08-30 NL NL1029828A patent/NL1029828C2/en not_active IP Right Cessation
- 2005-08-30 TW TW094129583A patent/TW200621291A/en unknown
- 2005-08-30 GT GT200500235A patent/GT200500235A/en unknown
-
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/en not_active Application Discontinuation
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/en unknown
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/en unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/en unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/en unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
ECSP077281A (en) | 2007-03-29 |
MX2007002441A (en) | 2007-05-04 |
IL181085A0 (en) | 2007-07-04 |
EA200700380A1 (en) | 2007-10-26 |
GT200500235A (en) | 2006-03-21 |
ZA200701802B (en) | 2008-08-27 |
NL1029828C2 (en) | 2006-10-20 |
NL1029828A1 (en) | 2006-03-01 |
WO2006024953A3 (en) | 2007-01-18 |
JP2008511610A (en) | 2008-04-17 |
CA2577999A1 (en) | 2006-03-09 |
NO20071322L (en) | 2007-05-29 |
KR20070042567A (en) | 2007-04-23 |
EP1789092A2 (en) | 2007-05-30 |
PE20060654A1 (en) | 2006-08-12 |
MA28908B1 (en) | 2007-10-01 |
BRPI0515118A (en) | 2008-07-01 |
CR8942A (en) | 2007-08-16 |
AP2007003919A0 (en) | 2007-02-28 |
AU2005278903A1 (en) | 2006-03-09 |
TW200621291A (en) | 2006-07-01 |
CN101010105A (en) | 2007-08-01 |
WO2006024953A2 (en) | 2006-03-09 |
UY29088A1 (en) | 2006-03-31 |
TNSN07078A1 (en) | 2008-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR050851A1 (en) | CONJUGATES OF HUMAN GROWTH HORMONE AND POLYETHYLENGLYCOL RAMIFIED WITH GLICEROL, PROCESS FOR THEIR PREPARATION AND METHODS OF USE OF THE SAME | |
AR047928A1 (en) | TETRAHYDROPIRIDOINDOL DERIVATIVES | |
ECSP10010684A (en) | MIXED AGONISTS, BASED ON GIP FOR THE TREATMENT OF METABOLIC DISORDERS AND OBESITY. | |
UY27720A1 (en) | MONOCYCLIC AROILPIRIDINONES, | |
WO2007059979A3 (en) | Allergy treatment by epicutaneous allergen administration | |
AR048878A1 (en) | TOPIC COMPOSITIONS OF METADONA AND METHODS FOR USE | |
AR069830A1 (en) | FACTOR VIII AND FACTOR OF VON WILLEBRAND MODIFIED RECOMBINANTS AND METHODS OF USE OF THE SAME | |
PE20080339A1 (en) | MODIFIED POLYPEPTIDES OF THE COAGULATION FACTOR IX AND USE OF THE SAME FOR TREATMENT | |
BR0313343A (en) | Use of a mixture of permeation agents, nail and periungual solutions and use of a nail and periungual solution | |
BRPI0513508A (en) | insulin-oligomer conjugates, formulations and uses of these | |
AR053651A1 (en) | COMBINED TREATMENT OF ANTIBODY ANTICTLA4 R AROMATASE INHIBITOR FOR BREAST CANCER | |
GT200500237A (en) | PIRIMIDINE DERIVATIVES | |
CU23213A3 (en) | DIFENILUREAS REPLACED WITH OMEGA-CARBOXIARILO AS RAF QUINASA INHIBITORS | |
CY1111177T1 (en) | FAINOTHEASINE UNION FOR INJURY HEALING | |
DK2321321T3 (en) | TRIAZOLO [4,5-D] PYRAMIDE INGREDIENTS AND USE THEREOF AS PURINE RECEPTOR ANTAGONISTS | |
CL2007001166A1 (en) | Compounds derived from condensed pyrimidine, pi3-kinase inhibitors; processes to prepare the compounds; pharmaceutical composition that includes them; use of the compounds in the preparation of medicaments; process to prepare the pharmaceutical composition; and kit that includes the pharmaceutical composition | |
AR051765A1 (en) | COMPOUNDS OF MOLECULES CONJUGATED WITH A REINFORCED ACTIVITY OF CELL ABSORPTION | |
EA201370006A1 (en) | LOCAL PHARMACEUTICAL COMPOSITION CONTAINING FLURBIPROPHEN | |
CR11562A (en) | BIS-PIRIDILPIRIDONAS AS ANTAGONISTS OF THE RECEIVER 1 OF THE CONCENTRATING HORMONE OF MELANINA | |
CL2007001748A1 (en) | Compound derived from 2-arylamino-4-aminopyrimidines, c-alpha protein kinase inhibitors; pharmaceutical compositions containing them; and its use to treat or prevent diabetes, cancer, cardiovascular diseases and others. | |
BR112017022755A2 (en) | glucopyranosyl lipid a and peanut allergen formulations for sublingual administration | |
ECSP067074A (en) | DERIVATIVES OF 4-PHENYL-PYRIMIDINE-2-CARBONITRILE | |
BRPI0518619A2 (en) | Method of treating cancer in a mammal, pharmaceutical combination, use of a pharmaceutical composition or combination and immunogenic composition | |
BR112012015437A2 (en) | substantially anhydrous stable storage topical composition | |
AR048672A1 (en) | DISINTEGRATION TABLETS THAT INCLUDE LICARBAZEPINA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |